Colleen Sweeney - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Colleen Sweeney's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Colleen Sweeney
Verified
Booker, Balcony TV
Brooklyn
Beats
Daily community news that is not business related
Content
Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer - British Journal of Cancer
By Maxine Umeh-Garcia, Colleen Sweeney| Nature Verified AbstractBackgroundLRIG1, the founding member of the LRIG (leucine-rich repeat and immunoglobulin-like domain) family of transmembrane proteins, is a negative regulator of receptor tyrosine kinases and a tumour suppressor. Decreased LRIG1 expression is consistently observed in cancer, across diverse tumour types, and is linked to poor patient prognosis. However, mechanisms by which LRIG1 is repressed are not fully understood.
Targeting the polyamine pathway-“a means” to overcome chemoresistance in triple-negative breast cancer
By Colleen Sweeney| The Journal of Biological Chemistry Verified Colleen Sweeney1 Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, California 95817 ↵1 To whom correspondence may be addressed: Dept. of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817. E-mail: casweeney{at}ucdavis.edu. Edited by Eric R.
Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer - British Journal of Cancer
By Maxine Umeh-Garcia, Colleen Sweeney| Nature Verified AbstractBackgroundLRIG1, the founding member of the LRIG (leucine-rich repeat and immunoglobulin-like domain) family of transmembrane proteins, is a negative regulator of receptor tyrosine kinases and a tumour suppressor. Decreased LRIG1 expression is consistently observed in cancer, across diverse tumour types, and is linked to poor patient prognosis. However, mechanisms by which LRIG1 is repressed are not fully understood.
Company Info